Insider Selling: Alignment Healthcare, Inc. (NASDAQ:ALHC) CFO Sells $473,412.80 in Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) CFO Robert Thomas Freeman sold 39,320 shares of the stock in a transaction dated Tuesday, October 8th. The stock was sold at an average price of $12.04, for a total value of $473,412.80. Following the sale, the chief financial officer now directly owns 194,609 shares in the company, valued at $2,343,092.36. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Robert Thomas Freeman also recently made the following trade(s):

• On Tuesday, October 1st, Robert Thomas Freeman sold 21,375 shares of Alignment Healthcare stock. The stock was sold at an average price of $10.66, for a total value of $227,857.50.
• On Friday, September 13th, Robert Thomas Freeman sold 14,500 shares of Alignment Healthcare stock. The stock was sold at an average price of $12.00, for a total value of $174,000.00.
• On Wednesday, September 11th, Robert Thomas Freeman sold 8,561 shares of Alignment Healthcare stock. The stock was sold at an average price of $10.01, for a total value of $85,695.61.
• On Wednesday, September 4th, Robert Thomas Freeman sold 1,650 shares of Alignment Healthcare stock. The stock was sold at an average price of $10.00, for a total value of $16,500.00.
• On Friday, July 19th, Robert Thomas Freeman sold 38,858 shares of Alignment Healthcare stock. The shares were sold at an average price of $10.01, for a total value of $388,968.58.
• On Wednesday, July 17th, Robert Thomas Freeman sold 22,100 shares of Alignment Healthcare stock. The shares were sold at an average price of $10.00, for a total value of $221,000.00.

Alignment Healthcare Trading Up 1.2 %

ALHC opened at $11.45 on Friday. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.61 and a quick ratio of 1.61. The company’s 50 day simple moving average is $10.03 and its two-hundred day simple moving average is $8.13. Alignment Healthcare, Inc. has a 1-year low of $4.46 and a 1-year high of $12.36. The firm has a market capitalization of $2.19 billion, a price-to-earnings ratio of -13.96 and a beta of 1.47.

Alignment Healthcare (NASDAQ:ALHC) last released its earnings results on Thursday, August 1st. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. Alignment Healthcare had a negative net margin of 6.85% and a negative return on equity of 101.10%. The business had revenue of $681.29 million for the quarter, compared to analyst estimates of $637.66 million. During the same period last year, the company posted ($0.15) EPS. The business’s revenue was up 47.3% on a year-over-year basis. Analysts expect that Alignment Healthcare, Inc. will post -0.67 EPS for the current fiscal year.

Analyst Ratings Changes

ALHC has been the topic of a number of analyst reports. Barclays raised their target price on Alignment Healthcare from $4.50 to $7.00 and gave the company an “underweight” rating in a research report on Monday, August 5th. Piper Sandler restated an “overweight” rating and set a $10.00 target price (up from $8.00) on shares of Alignment Healthcare in a research report on Tuesday, August 6th. KeyCorp initiated coverage on Alignment Healthcare in a research report on Friday. They set a “sector weight” rating on the stock. Robert W. Baird raised their target price on Alignment Healthcare from $10.00 to $11.00 and gave the company an “outperform” rating in a research report on Wednesday, August 14th. Finally, TD Cowen raised their price target on shares of Alignment Healthcare from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Tuesday, August 6th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Alignment Healthcare has a consensus rating of “Moderate Buy” and an average target price of $9.83.

Institutional Trading of Alignment Healthcare

Several institutional investors have recently made changes to their positions in the company. Deerfield Management Company L.P. Series C raised its position in shares of Alignment Healthcare by 31.8% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 10,901,485 shares of the company’s stock valued at $85,250,000 after buying an additional 2,630,788 shares during the period. Vanguard Group Inc. raised its position in shares of Alignment Healthcare by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 9,239,472 shares of the company’s stock valued at $45,828,000 after buying an additional 93,262 shares during the period. Hood River Capital Management LLC raised its position in shares of Alignment Healthcare by 6.4% during the 2nd quarter. Hood River Capital Management LLC now owns 3,106,690 shares of the company’s stock valued at $24,294,000 after buying an additional 185,854 shares during the period. William Blair Investment Management LLC raised its position in shares of Alignment Healthcare by 94.4% during the 2nd quarter. William Blair Investment Management LLC now owns 3,104,681 shares of the company’s stock valued at $24,279,000 after buying an additional 1,507,759 shares during the period. Finally, Renaissance Technologies LLC raised its position in shares of Alignment Healthcare by 16.8% during the 2nd quarter. Renaissance Technologies LLC now owns 1,565,800 shares of the company’s stock valued at $12,245,000 after buying an additional 225,000 shares during the period. Hedge funds and other institutional investors own 86.19% of the company’s stock.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.